Rosa Azzaro
YOU?
Author Swipe
View article: Data from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Data from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Purpose:To identify predictive factors of nivolumab sensitivity, peripheral blood NKs and regulatory T-cell (Treg) were evaluated in patients with metastatic renal cell carcinoma (mRCC) enrolled in the REVOLUTION trial.Experimental Design:…
View article: Supplementary Figure S13 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S13 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S13. T0-T1 values (after one month of nivolumab) between PD-1+ Tregs and Helios+Tregs in Responder and Not Responder patients
View article: Supplementary Figure S5 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S5 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S5. Nivolumab did not significantly affect peripheral NKs and Tregs
View article: Supplementary Figure S3 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S3 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S3. Pretreatment NKs and Tregs in mRCC-REV patients
View article: Supplementary Figure S11 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S11 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S11. HLA class I in primary RCC from REV patients
View article: Supplementary Figure S10 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S10 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S10. .632+ cross validation bootstrap ROC curves and the optimum T1 cut-off values of CD3+ and KIR2DL2/DL3+NKs to determine the outcome of REV patients
View article: Supplementary Tables S1-S12 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Tables S1-S12 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Table S1. Antibodies used for flow cytometry Supplementary Table S2. mRCC-REV patients characteristics Supplementary Table S3. HDs characteristics Supplementary Table S4. Representativeness of Study Participants Supplementary…
View article: Supplementary Figure S7 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S7 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S7. Pretreatment NKs and Tregs subpopulations in mRCC-REV Long Responder (LR) patients vs Not-Responders (NR).
View article: Supplementary Figure S12 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S12 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S12. Correlation between pretreatment of PD-1+Tregs and Helios+Tregs in Responder and Not-Responder patients.
View article: Supplementary Figure S6 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S6 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S6. Swimmer’s plot of nivolumab-treated mRCC patients.
View article: Supplementary Figure S4 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S4 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S4. Pretreatment NKs co-expression of PD-1 and KIR2DL1or KIR2DL2/DL3 in mRCC-REV patients.
View article: Supplementary Figure S1 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S1 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S1. Gating strategy for identification of Tregs and NKs in peripheral blood.
View article: Supplementary Figure S8 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S8 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S8. .632+ cross validation bootstrap ROC curves and the optimum pretreatment cut-off values of KIR2DL2/DL3+NKs and Helios+Tregs to determine the outcome of REV patients
View article: Supplementary Figure S2 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S2 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S2. Correlation between age and pretreatment NKs and Tregs immune subsets cells in mRCC-REV patients and HDs.
View article: Supplementary Figure S9 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Supplementary Figure S9 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Supplementary Figure S9. Association between the KIR2DL2/DL3+NKs/Helios+Tregs values and response to nivolumab treatment.
View article: KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer Open
Purpose: To identify predictive factors of nivolumab sensitivity, peripheral blood NKs and regulatory T-cell (Treg) were evaluated in patients with metastatic renal cell carcinoma (mRCC) enrolled in the REVOLUTION trial. Experimental Desig…
View article: Patient blood management in major digestive surgery: Recommendations from the Italian multisociety (ACOI, SIAARTI, SIdEM, and SIMTI) modified Delphi consensus conference
Patient blood management in major digestive surgery: Recommendations from the Italian multisociety (ACOI, SIAARTI, SIdEM, and SIMTI) modified Delphi consensus conference Open
Patient blood management (PBM) is defined as the timely application of evidence-based medical and surgical concepts designed to maintain a surgical patient’s hemoglobin concentration, optimize hemostasis, and minimize blood loss in an effo…
View article: Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients
Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients Open
Background Nivolumab is an anti-PD1 antibody that has dramatically improved metastatic melanoma patients’ outcomes. Nevertheless, many patients are resistant to PD-1 inhibition, occasionally experiencing severe off-target immune toxicity. …
View article: Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients
Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients Open
Background Nivolumab is an anti-PD1 antibody that has dramatically improved metastatic melanoma patients’ outcomes. Nevertheless, many patients are resistant to PD-1 inhibition, occasionally experiencing severe off-target immune toxicity. …
View article: Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents
Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents Open
Background CD73 is an ectonucleotidase producing the immunosuppressor mediator adenosine. Elevated levels of circulating CD73 in patients with cancer have been associated with disease progression and poor response to immunotherapy. Immunos…
View article: Crosstalk between Macrophages and Myxoid Liposarcoma Cells Increases Spreading and Invasiveness of Tumor Cells
Crosstalk between Macrophages and Myxoid Liposarcoma Cells Increases Spreading and Invasiveness of Tumor Cells Open
Myxoid liposarcoma (MLPS) is the second most common subtype of liposarcoma and has tendency to metastasize to soft tissues. To date, the mechanisms of invasion and metastasis of MLPS remain unclear, and new therapeutic strategies that impr…
View article: Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy Open
Background Inhibitors of immune checkpoint programmed cell death protein 1 (PD-1) receptor on T cells have shown remarkable clinical outcomes in metastatic melanoma. However, most patients are resistant to therapy. Production of extracellu…
View article: Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma
Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma Open
Chondrosarcomas (CHS) are malignant cartilaginous neoplasms with diverse morphological features, characterized by resistance to chemo- and radiation therapies. In this study, we investigated the role of tumor-associated macrophages (TAM)s …
View article: Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications
Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications Open
Although sequencing artifacts can be identified in targeted sequencing of cfDNA, tumor heterogeneity and CHIP are likely to influence the concordance between plasma and tissue testing.
View article: Correction: Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy
Correction: Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy Open
[This corrects the article DOI: 10.1371/journal.pone.0212033.].
View article: Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy
Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy Open
Genotype 1b is still the most prevalent, even if shows a significantly increase in the under 40 years old population. Instead, genotype 3a seems to have a moderate increase among young people. Overall, the alarming finding is the "returnin…